Overview of prognostic models in CLL.
Wierda |
Rossi |
CLL-IPI [13] | |
---|---|---|---|
N of patients | 930 with Rai 0–1 stage | 637 (1,274 samples) | 3,472 |
Clinical implication | TTFT | OS at 5 yr | OS at 5 yr |
Clinical and biochemical markers | LDH | Age | Age>65 yr (1) |
Involved LN sites | Rai stage | Binet B–C or Rai I–IV (1) | |
Diameter palpable LN | β2-microglobulin (3.5 mg/L) (2) | ||
Genetic markers | Del(11q) by FISH | IGHV unmutated | TP53 or del(17p) (4) |
Del(17p) by FISH | TP53/BIRC3 | IGHV unmutated (2) | |
IGHV unmutated | NOTCH1/SF3B1/del11q22-q23 | ||
Trisomy 12 or wild type | |||
Del13q14 | |||
Risk groups | Weighted formula | High: 50.9% of OS | Very high (7–10): 23.3% |
Intermediate: 65.9% | High (4–6): 63.3% | ||
Low: 77.6% | Intermediate (2–3): 79.3% | ||
Very low: 86.9% | Low (0–1): 93.0% |
Abbreviations: ALC, absolute lymphocyte count; CLL-IPI, International CLL-Integral Prognostic Index; FISH, fluorescence in situ hybridization; IgA, immunoglobulin A; IGHV, immunoglobulin heavy chain variable region gene; LDH, lactate dehydrogenase; LN, lymph node; OS, overall survival; TTFT, time to first treatment.